Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday.
10 Biggest Price Target Changes For Monday
Raymond James cut The Estée Lauder Companies Inc. (NYSE: EL) price target from $390 to $345. Estée Lauder shares rose 0.4% to $264.95 in pre-market trading.
21 Stocks Moving in Monday’s Pre-Market Session
Gainers
Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack production at high voltage R&D facility in Monrovia, California.
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $19
HC Wainwright & Co. analyst Edward White maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and lowers the price target from $68 to $19.
TG Therapeutics Retracts FDA Request For Ublituximab / Ukoniq Combo In Blood Cancers
TG Therapeutics Inc’s (NASDAQ:TGTX) new data showed that ublituximab /Ukoniq, dubbed U2, had an elevated risk of death in the phase…
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
TG Therapeutics Announces Data Presentations From The ULTIMATE I & II Phase 3 Trials Of Ublituximab In Multiple Sclerosis Presented At The American Academy Of Neurology Annual Meeting
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented over the
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.